A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI)

Trial Profile

A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs SB 623 (Primary)
  • Indications Brain injuries
  • Focus Therapeutic Use
  • Acronyms STEMTRA
  • Sponsors SanBio
  • Most Recent Events

    • 01 Apr 2018 According to a SanBio media release, the company plans to publish clinical trial results form this TBI study by the end of the fiscal year ending January 2019 and file for approval in the fiscal year ending January 2020.
    • 01 Apr 2018 Status changed from recruiting to active, no longer recruiting, according to a SanBio media release.
    • 13 Mar 2018 According to a SanBio media release, enrollment for this trial is close to complete.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top